BIOMAT Database Logo BIOMAT Database Logo

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. 1988

K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Klinik für Nuklearmedizin, Bereich Medizin (Charitè), Humboldt-Universität, Berlin, German Democratic Republic.

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.
January 1988, Acta oncologica (Stockholm, Sweden),
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
April 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
[Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
April 1993, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
September 1991, The British journal of radiology,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
[Treatment of symptomatic bone metastases of prostatic carcinoma with strontium (Sr-89) chloride: initial experience].
March 1992, Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
[Strontium-89 diagnosis and therapy of bone metastases].
January 2004, Voprosy onkologii,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
July 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Systemic radionuclide therapy of bone metastases with strontium-89.
February 1994, Oncology (Williston Park, N.Y.),
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Strontium-89 therapy for the pain of osseous metastases.
April 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
K Buchali, and H J Correns, and M Schuerer, and D Schnorr, and H Lips, and K Sydow
Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.
August 2003, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!